A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) ("the Company"), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter,...
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to...
This KOL Panel features Mitch Pinheiro, Senior Research Analyst at Sturdivant & Co. joins Lytham Vice President, Adam Lowensteiner for a deep dive into market trends within the consumer sector. This KOL Panel was recorded during the Lytham Partners 2024 Investor...
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in...
NEW YORK, NY / January 8, 2024 / Dror Ortho-Design, Inc. ("Dror" or the "Company") (OTC PINK:DROR), an AI-based orthodontic platform company that has developed a proprietary solution to correct people's smiles by straightening teeth using pulsating air delivered by a...
Arco, Italy, Dec. 20, 2023 -- AQUAFIL RANKED FIRST AMONG GLOBAL COMPANIES IN THE "TEXTILES" SUBINDUSTRY ACCORDING TO MORNINGSTAR SUSTAINALYTICS ESG RISK RATING Arco, December 20, 2023 - Aquafil S.p.A. [ECNL:IM] [ECNLF:OTCQX] ranked as the top company globally in the...
Tru Niagen is now available to US troops through an exclusive Military program LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, is proud to announce its inaugural initiative to...
Building on a growing body of research showcasing NR as a potential therapeutic strategy for PD, this is the first clinical study to showcase the safety, tolerability, and beneficial metabolic effects of high-dose NR at 3,000 mg per day LOS ANGELES - ChromaDex Corp....
Management Presentation to be webcast live on November 21, 2023 at 2:30PM CET/8:30AM Eastern Standard TimeARCO, Italy, Nov. 17, 2023 -- Aquafil SpA (ECNLF:OTCQX - ECNL:IM), based in Arco (TN) Italy, pioneer of circular economy, today announced that it will be hosting...
This is the longest Niagen NR clinical trial to date spanning two years and showcases that long-term Niagen NR is safe and well tolerated LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), one of the global authorities on Nicotinamide Adenine Dinucleotide (NAD+) and healthy...